Plain-English translation of NCT04180085 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This pilot study is testing a medication called belatacept to see if it can help protect your kidneys after a heart transplant. Currently, most heart transplant patients take medications that work well to prevent rejection, but these drugs can damage the kidneys over time. Researchers believe this medication might offer similar protection against rejection while being gentler on the kidneys.
Many heart transplant patients develop kidney problems because the standard anti-rejection medications can harm kidney function in both the short and long term. This trial exists to see whether this medication could offer the same life-saving protection against rejection while preserving kidney health and preventing the need for dialysis or a kidney transplant.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive the new medication in combination with a reduced dose of your current anti-rejection drugs, along with a specific induction therapy. You will need to attend regular clinic visits to have your kidney function monitored through blood tests and to check how well your heart transplant is working. The study involves about 25 heart transplant patients at Nantes University Hospital, and your participation will help doctors understand whether this medication can better protect transplant recipients' kidneys.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
France